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a b s t r a c t
Macrophage migration inhibitory factor (MIF) of Ostertagia ostertagi, an abomasal parasite of cattle, was
characterised in the present study. Phylogenetic analysis identified at least three O. ostertagi MIFs (Oos-
MIFs), each encoded by a distinct transcript: Oos-MIF-1.1, Oos-MIF-1.2 and Oos-MIF-2. Oos-MIF-2 is only
distantly related to Oos-MIF-1s, but has higher sequence similarity with the Caenorhabditis elegansMIF2.
Oos-MIF-1.1 and Oos-MIF-1.2 are similar (93%) and thus collectively referred to as Oos-MIF-1 when
characterised with immunoassays. Recombinant Oos-MIF-1.1 (rOos-MIF-1.1) is catalytically active as a
tautomerase. A mutation (rOos-MIF-1.1P1G) or duplication of Pro1 residue (rOos-MIF-1.1P1+P) resulted
in reduced oligomerisation and loss of tautomerase activity. The tautomerase activity of rOos-MIF-1.1
was only partially inhibited by ISO-1 but was abrogated by a rOos-MIF-1.1-specific antibody. Oos-MIF-
1 was detected in all developmental stages of O. ostertagi, with higher levels in the adult stage; it was also
detected in adult worm excretory/secretory product. Oos-MIF-1 was localised to the hypodermis/muscle,
reproductive tract and intestine, but not to the cuticle. rOos-MIF-1.1, but not rOos-MIF-1.1P1G, was able
to specifically bind to human CD74, a MIF cell surface receptor, with an affinity comparable with human
MIF. Immunostaining indicated that macrophages were able to internalise rOos-MIF-1.1, further support-
ing receptor-mediated transportation. Herein we also show that rOos-MIF-1.1 inhibited migration of
bovine macrophages and restored glucocorticoid-suppressed, lipopolysaccharide-induced TNF-a and
IL-8 in human and/or bovine macrophages. Given its dual role in self-regulation and molecular mimicry,
this secreted parasite protein warrants investigation as a vaccine candidate against O. ostertagi infections
in cattle.
Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc.
1. Introduction
Parasitic nematodes are notorious in their ability to regulate
host immunity and evade immune surveillance. In part, this effect
is accomplished by producing bioactive molecules which possess
potent immunoregulatory functions. To date, macrophage
migration inhibitory factor (MIF), a cytokine activity first described
decades ago, has been characterised in Caenorhabditis elegans and a
number of parasitic nematodes (Vermeire et al., 2008). Mammalian
MIF is involved in septic shock (Bernhagen et al., 1993), regulates
macrophage (Calandra et al., 1994; Onodera et al., 1997) and
lymphocyte responses, and affects endocrine function (Bacher
et al., 1996; Abe et al., 2001; Fingerle-Rowson and Bucala, 2001).
MIF also inhibits the random migration of monocytes/
macrophages, the anti-inflammatory effects of glucocorticoids
(Calandra et al., 1994), and it upregulates Toll-like receptor 4
(TLR4) expression by immune cells (Roger et al., 2003) and pro-
inflammatory cytokines (TNFa, IL-1b, IL-6, IL-8 and IL-12) (Calan-
dra et al., 1994; Bacher et al., 1996; Donnelly et al., 1999). MIF is
produced by a wide variety of cell types, including lymphocytes,
monocytes/macrophages, endothelial cells and fibroblasts
(Calandra and Roger, 2003). Its biological effects are mediated by
a receptor complex involving CD74 (Leng et al., 2003), CD44 (Shi
et al., 2006) and CXC chemokine receptors (Bernhagen et al., 2007).
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MIF possesses oxidoreductase and tautomerase activities which
may be associated with its immunological function (Sun et al.,
1996a,b; Suzuki et al., 1996). The protein’s conserved C–XX–C
motif is associated with the oxidoreductase activity, and the
N-terminal proline (Pro1) acts as a catalytic base for tautomerase
activity (Bendrat et al., 1997; Stamps et al., 1998). MIF tautomerase
activity can be inhibited by ISO-1 and other small-molecule
inhibitors (Lubetsky et al., 2002; Cournia et al., 2009). The crystal
structures and sedimentation velocities of bioactive human and
mouse MIFs indicate they exist as homotrimers (Philo et al.,
2004), although a mixture of monomers, dimers and trimers have
been detected (El-Turk et al., 2008). This is similar to a recent
report for Neospora caninum MIF (Qu et al., 2013).
Ostertagia ostertagi is a nematode parasite infecting the aboma-
sum of cattle. It is highly prevalent in temperate regions of the
world and causes sustained production losses (Williams et al.,
1993). Gastrointestinal parasite control is heavily dependent on
the use of anthelmintics; however drug resistance is rapidly
emerging and requires development of alternatives to drug control.
Investigation of the host–parasite interaction, particularly immu-
nomodulation mediated by parasitic cytokines, will aid in further
understanding the host response to infection and parasite evasion,
and facilitate the development of immunological control measures.
MIF homologues have been characterised in a number of parasitic
nematodes including Brugia malayi, Trichinella spiralis, Strongyloides
ratti, Wuchereria bancrofti, Teladorsagia circumcincta, and
Ancylostoma ceylanicum. In each case, they appear to exhibit
similar bioactivities to the MIFs of their mammalian hosts (Falcone
et al., 2001; Tan et al., 2001; Zang et al., 2002; Cho et al., 2007;
Vermeire et al., 2008; Nisbet et al., 2010; Sharma et al., 2012;
Younis et al., 2012). In the present study, a secretory O. ostertagi
MIF (Oos-MIF) was cloned and expressed in Escherichia coli and
its production, structural and enzymatic properties, cellular
localisation and biological functions were characterised. Oos-
MIF-1 isoforms (1.1 and 1.2) are highly conserved (93%), and thus
are collectively described as Oos-MIF-1 in immunoassays because
they may not be distinguishable by polyclonal antibodies. The
results of the present study indicate that Oos-MIF-1 is present at
various stages of development, suggesting that this cytokine may
be involved in regulating host protection and therefore represents
a vaccine candidate against seasonal re-infection.
2. Materials and methods
2.1. Oos-MIF gene cloning and sequencing
A complete open reading frame (ORF) for Oos-MIF was obtained
from Oos-MIF cDNA sequences (GenBank accession numbers,
BQ457770, BQ457911), an expressed sequence tag (EST) sequence
(OS00782) and mRNA transcripts (Oost_isotig14764, Oost_iso-
tig14765, http://www.nematode.net). This Oos-MIF was named
Oos-MIF-1.1 (see Section 3.1). Primers were designed to amplify
the Oos-MIF gene from adult worm cDNA using a forward primer
(50-GGAATTCCATATGCCGGTTTTCTC-30; NdeI site underlined) and a
reverse primer (50-ATAAAGCTTTCAAGCAAAAGTTCTGC-30; HindIII
site underlined). A forward primer, 50-GGAATTCCATATGGGCG
TTTTCTCATTCCACAC was used to produce the mutant, rOos-MIF-
1.1P1G, wherein the proline (Pro) at position 1 was replaced with
glycine (Gly). A forward primer, 50-GGAATTCCATATGCCGCCG
GTTTTCTCATTC was used to produce a second Oos-MIF-1.1 mutant,
rOos-MIF-1.1P1+P, inwhich an additional Prowas inserted between
Pro1 and Val2. Total RNA was isolated from adult O. ostertagi using
the RNeasy Mini Kit (Qiagen, Maryland, USA). Two micrograms of
total RNAwere used to synthesise cDNA using theM-MuLV Reverse
Transcriptase Kit (New England Biolabs, Inc, Ipswich, MA, USA). The
polymerase chain reaction (PCR)wasperformedas follows: 95 C for
1 min followed by 35 cycles at 95 C for 40 s, 55 C for 30 s, 72 C for
40 s with a final extension of 72 C for 10 min. The product was
purified using a PCR purification kit (Promega, Madison, WI, USA)
and ligated into the pGEM-T vector (Promega). The recombinant
plasmid was extracted from the E. coli by the Wizard Plus SV
Minipreps (Promega) and sequenced by Functional Biosciences
Inc., Madison, WI, USA.
2.2. Expression, endotoxin removal and purification of rOos-MIF-1.1
and its mutants, and anti-rOos-MIF-1.1 antibody production
To express the recombinant proteins, the rOos-MIF-1.1, rOos-
MIF-1.1P1G and rOos-MIF-1.1P1+P genes were subcloned into
the pET26b(+) vector (EMD Millipore, San Diego, CA, USA), trans-
formed into E. coli BL21 (DE3) (Novagen, Madison, WI, USA) under
kanamycin (50 lg/ml) selection and induced at 30 C for 10 h in
the presence of 1 mM isopropyl thiogalactopyranoside (IPTG).
After centrifugation at 4,000g for 20 min at 4 C, the bacteria were
lysed by five freeze–thaw cycles in lysis buffer (50 mM NaH2PO4,
300 mM NaCl, pH 8.0) followed by digestion with 10 lg/ml of
DNase/RNase for 30 min at 37 C. The recombinant protein was
found in the soluble fraction following centrifugation at 20,000g
for 20 min at 4 C.
Endotoxin was removed using Triton X-114 (Sigma, St. Louis,
MO, USA) prior to HPLC purification (Aida and Pabst, 1990; Qu
et al., 2013). In brief, Triton X-114 was added to the soluble lysate
to a final concentration of 1%, vortexed for 10 s, incubated on ice
for 5 min then vortexed again. Phase separation occurred when
the mix was incubated at 37 C for 10 min and centrifuged at
20,000g for 2 min at 38 C. The upper aqueous phase containing re-
combinant protein was retreated seven additional times until
endotoxin removal was complete. All recombinant proteins were
purified by HPLC using a size exclusion column (7.7  300 mm,
Biosuite 5 lm HR; Waters, MA, USA) and eluted with a mobile
phase of PBS (50 mM K2HPO4, 200 mM NaCl, pH 7.2). The fractions
were collected and analysed by SDS–PAGE; a Bicinchoninic Acid
(BCA) assay (Thermo Scientific, Rockford, Illinois, USA) was used
to determine protein concentrations. The endotoxin levels in Triton
X-114 extracted rOos-MIF preparations were undetectable using
the endotoxin detection kit (Limulus Amebocyte Lysate
QLC-1000, Lonza, Walkersville, MD, USA).
Sheep antisera raised against rOos-MIF-1.1 were produced by
immunising a sheep with purified rOos-MIF-1.1 (200 lg/injection).
Yearling sheep were pre-screened for cross-reactivity to crude O.
ostertagi antigen using Western blotting and the sheep that had
undetectable cross-reactivity to O. ostertagi antigen was used to
produce antiserum. Sera were collected following four immunisa-
tions at 3-week intervals and stored at 20 C until used. Animal
care and use was approved by Beltsville Agricultural Research Cen-
ter Animal Care and Use Committee, MD, USA.
2.3. Preparation of crude parasite proteins
Embryonated eggs were collected from feces by the flotation
method using saturated sucrose followed by washes in tap water.
Eggs were further purified by Lymphocyte Separation Medium
(specific gravity, 1.077; Mediatech Inc., Manasses, VA, USA)
followed by two washes in PBS. L3 and adult O. ostertagi were
collected and produced using the Baerman technique (for L3s)
and/or gel migration method (for adult worms) as described previ-
ously (Williams et al., 1987). Crude parasite protein was generated
from embryonated eggs, L3s and adult worms by homogenisation
in liquid nitrogen in the presence of 1 mM phenylmethylsulfonyl
fluoride (PMSF) and 10 mM EDTA. To prepare excretory/secretory
(ES) products, adult parasites were washed three times with PBS
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then cultured in serum-free DMEM supplemented with 100 pen-
icillin/streptomycin, gentamicin (Mediatech, Inc.), Fungizone, and
glutamine (Hyclone, Logan, UT, USA) at 37 C or 4 C for 24 h
(de Graaf et al., 1995). Culture medium was collected by removing
the worms using sedimentation followed by centrifugation at
200,000g at 4 C for 30 min. A protease inhibitor cocktail (Roche,
Mannheim, Germany) was added immediately after the parasites
were removed from the culture medium. The resultant superna-
tant was concentrated by ultrafiltration (Millipore, Billerica, MA,
USA) with a molecular mass cutoff of 3,000 Da. The protein concen-
tration of all protein samples was determined by a BCA assay
(Thermo Scientific). Equal quantities of the total proteins derived
from embryonated eggs, L3s and adult worms were analysed by
SDS–PAGE and the relative amount of Oos-MIF-1 was determined
by Western blotting followed by densitometry.
2.4. Western blotting
Western blotting was performed as described previously (Qu
et al., 2013). Briefly, samples were separated on a 15% SDS–PAGE
gel under reducing conditions. After protein transfer, the blot
was incubated in blocking solution (3% skim milk in PBS) for 1 h
followed by incubation in sheep anti-Oos-MIF-1.1 serum
(1:2,000) in blocking solution for 1 h at room temperature.
After five washes with wash buffer (0.05% Tween 20 in PBS), the
blot was incubated at room temperature for 1 h in rabbit anti-
sheep IgG–HRP (1:5,000) followed by five washes with wash
buffer. The blot was developed with a chemiluminescent substrate
(SuperSignal West Dura Exrended Duration Substrate, Thermo-
Fisher, Rockford, IL, USA) according to the manufacturer’s
instructions. The image was captured and analysed using a
ChemiImager™ 4,400 Low Light Imaging system (Alpha Innotech
Corporation, San Leandro, CA, USA). Integrated O.D. of Oos-
MIF-1-specific bands was determined by the above imaging
system.
2.5. Cross-link assay of rOos-MIF-1.1 and its mutant
An Oos-MIF-1.1 and mutant cross-linking experiment was per-
formed as described previously (Mischke et al., 1998; Qu et al.,
2013). In brief, rOos-MIF-1.1 and its mutants at a concentration
of 2 lg/ml in 50 mM potassium phosphate buffer at pH 6.5 were
incubated in the presence of 1% glutaraldehyde (Sigma) for 3 h at
RT. The reaction was stopped and the cross-linked products were
stabilised in 50 mM NaBH4 for 20 min, followed by washing with
0.01% sodium deoxycholate (Sigma). The protein then was precip-
itated by lowering the pH to 2.0 with trichloroacetic acid (Sigma).
After centrifugation (10 min, 14,000g), the pellet was washed twice
with 100 ll of aectone and heated to 75 C for 10 min in 2 LDS
Sample Buffer (NuPAGE, Invitrogen, Carlsbad, CA, USA). Samples
were analysed by SDS–PAGE under reducing conditions and silver
staining (Sigma).
2.6. Tautomerase assays
The tautomerase activity of rOos-MIF-1.1 and its mutants were
determined using L-dopachrome methyl ester as reported previ-
ously (Pennock et al., 1998; Qu et al., 2013). In brief, 48 ll of
10 mM L-3,4-dihydroxyphenylalanine methyl ester (Sigma) and
32 ll of 20 mM sodium periodate (Sigma) were mixed with
720 ll of buffer (50 mM potassium phosphate, 1 mM EDTA, pH
6.2) in a 1 ml polystyrene disposable cuvette to generate
L-dopachrome methyl ester. The proteins were added to the
cuvette and read at A475 for 20 min at 10 s intervals using a spec-
trophotometer (Beckman, Atlanta, GA, USA). Mouse MIF (Research
& Diagnostics Systems, Inc., Minneapolis, MN, USA)) was used as a
positive control. To determine the effect of sheep-anti-rOos-
MIF-1.1 antibody on tautomerase activity, rOos-MIF-1.1 was incu-
bated with different concentrations of sheep-anti-rOos-MIF-1.1
antibody for 1 h at room temperature prior to tautomerase assay.
2.7. Immunolocalisation of Oos-MIF-1
Adult O. ostertagi parasites were harvested, washed briefly in
PBS, fixed in 10% neutral formalin for 12 h, embedded in paraffin
and sectioned at 5 lm thickness for staining (HistoServe Inc., Ger-
mantown, MD, USA). The sections were deparaffinised, quenched
with 3% H2O2 and rehydrated prior to pepsin digestion (0.4% pepsin
in 0.01 N HCl) at 37 C for 15 min. The slides were washed twice
with 0.75% Brij 35 (Sigma) in PBS (BRIJ–PBS) and blocked with
0.5% sodium caseinate in BRIJ–PBS for 10 min before incubation
for 30 min at room temperature with the sheep anti-Oos-MIF-1.1
antibody (1:1,000). After washing, rabbit anti-sheep IgG–horseradish
peroxidase (HRP) (1:500) and Dako AEC substrate chromogen
(Dako, Carpinteria, CA, USA) were used to visualise antibody
binding. Hematoxylin was used as counter-stain prior to applying
a coverslip. Pre-bleed sheep serum of similar dilution was used
as a negative control. Micrographs were taken using the Zeiss
Axioskiope 2 Plus microscope (Zeiss, Thornwood, NY, USA).
2.8. rOos-MIF-1.1 internalisation by immune cells and competitive
binding to the CD74
rOos-MIF-1.1 internalisation by immune cells was determined
using the murine macrophage cell line RAW264.7 and bovine cell
line BoMac. Cells cultured in RPMI 1,640 supplemented with 10%
FBS, 25 mM glutamine and 50 lg/ml of gentamicin (complete med-
ium) were seeded in 24-well plates and incubated overnight at
37 C in the presence of 5% CO2. At 60–80% confluency, cells were
rinsed twice with complete medium and co-cultured with or with-
out 10 lg/ml of rOoMIF-1.1 overnight. Cells then were washed
twice with PBS and fixed with cold methanol/acetone (1:1) for
20 min at 20 C. The fixative was removed and the cells were
air-dried and stored at 4 C until stained. Prior to staining, cells
were rehydrated with PBS for 5 min, washed three times with PBS
then blocked at room temperature for 1 h in 0.3% Triton X-100,
1% BSA, 3% non-fat skim milk, 5% FBS in PBS, pH 7.2. Sheep anti-
rOos-MIF-1.1 antibody was diluted 1:500 in antibody dilution
buffer (1% BSA, 0.3% Triton X-100 in PBS, pH 7.2), added to wells
and incubated overnight at 4 C. Controls included secondary
antibody alone and medium alone. Following five washes with
wash buffer, rabbit anti-sheep IgG labeledwith Alexa 488 (KPL, Gai-
thersburg, MD, USA) diluted 1:1,000 in antibody dilution buffer was
added and incubated for 2 h at room temperature in the dark. Plates
were washed four times then incubated with DAPI (1 lg/ml) (Invit-
rogen) for 5 min at RT. Plates were washed three times prior to the
addition of the mounting medium (glycerol and 10x PBS mixture at
1:9). Images were captured using an inverted, phase-contrast, fluo-
rescence microscope (Olympus, Center Valley PA, USA).
rOos-MIF-1.1 and rOos-MIF-1.1P1G were tested for binding to
the human MIF receptor, CD74, as described previously (Leng
et al., 2003; Qu et al., 2013). In brief, 96-well plates were coated
with recombinant, soluble CD74 ectodomain (sCD7473–232).
Biotinylated recombinant human MIF (rhMIF; 2.3 lg/ml) (Roche
Applied Sciences, Indianapolis, Indiana, USA) was added in
triplicate wells, together with increasing concentrations of purified
(non-biotinylated) rhMIF, rOos-MIF-1.1 or rOos-MIF-1.1P1G. The
bound biotinylated rhMIF was detected by streptavidin-conjugated
alkaline phosphatase (R&D) using the p-nitrophenyl phosphate
substrate (Sigma). Plates were read at 405 nm and data were
plotted as the percentage of A405 relative to wells containing
biotinylated rhMIF alone.
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Fig. 1. Macrophage migration inhibitory factor gene and protein sequence alignment and phylogenetic analysis. (A) Comparison of amino acid sequences of macrophage
migration inhibitory factor orthologues from selected nematodes together with bovine, human and mouse migration inhibitory factor using ClustalW. Similar to mammalian
macrophage migration inhibitory factors, it is predicted that Methionine of Ostertagia ostertagiMIF-1.1 (Oos-MIF-1.1) is also removed in both native and recombinant proteins
(Bernhagen et al., 1994; Sun et al., 1996b). The GenBank accession numbers are as follows: Teladorsagia circumcincta MIF (Tci-MIF-1), CBI68362; Caenorhabditis elegans MIF
(Cel-MIF-1), NP_499536; Brugia malayi MIF (Bma-MIF-1), AAB60943; Ascaris suum MIF (Asu-MIF-1), ABM30179.1; Trichinella spiralis MIF (Tsp-MIF), CAB46354; Trichuris
trichiura MIF (Ttr-MIF), CAB46355; Bos taurus MIF (bMIF), NP_001028780; Homo sapiens MIF (hMIF), NP_002406; Mus musculus MIF (mMIF), NP_034928. Identical residues
are indicated by an asterisk; the six amino acid residues in mammalian macrophage migration inhibitory factors previously predicted to interact with the tautomerase
substrate are marked by open triangles and the Cysteine in the CXXC motif is marked by filled triangles. (B) Alignment of Oos-mif-1.1 and Tci-mif-1 (FN599526) cDNA
sequences. Alignment demonstrates divergence at 14 nucleotide positions (shaded). Corresponding amino acid sequences (Oos-MIF1.1) are identical to A. The codon (CCG) for
proline at aa position 2 is underlined to indicate that this codon sequence was unknown; however, CCG was used because one of the Oos-MIF-1mRNA transcript (OS00782)
starts with the sixth nucleotide G, and there is only one proline codon that has a G at the third position. (C) Amino acid sequence alignment for Oos-MIF-1.1, Oos-MIF-1.2 and
Oos-MIF-2. Conserved residues key to tautomerase activity are marked by an open triangle. (D) Phylogenetic trees of MIF-1 (a) and MIF-2 (b) protein sequences. The neighbor
joining trees were bootstrapped using the MUSCLE program and analysed by the PhyML program, followed by viewing with tree viewer TreeDyn (www.phylogeny.fr). The
branch nodes are annotated with values indicating bootstrap support for each branch. Amino acid sequences used in Da are the same as those in A, including all Oos-MIFs,
selective nematode MIF-1s and mammalian macrophage migration inhibitory factors. Amino acid sequences used in Db include all Cel-MIFs, characterised nematode MIF-2s
and all Oos-MIFs. The GenBank accession numbers are as follows: Cel-MIF-1, NP_499536; Cel-MIF-2a, NP_001256386.1; Cel-MIF-3, NP_492069.1; Cel-MIF-4, NP_500968.1;
Bma-MIF-2, AAF91074; Asu-MIF-2, ADY48840; Oos-MIF-1.1, KJ427776; Oos-MIF-1.2, OS04085; Oos-MIF-2, Oost_isotig21269.
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2.9. Regulation of glucocorticoid action and migration inhibition of
bovine adherent peripheral blood mononuclear cells (aPBMC) by rOos-
MIF-1.1
The ability of rOos-MIF-1.1 to counter-regulate glucocorticoid
action was tested as described by Roger et al. (2005). Bovine
aPBMCs were isolated by culturing whole PBMC in 24-well plates
for 24 h and removing the non-adherent cells. aPBMCs and human
monocyte cells (U937, American Type Culture Collection (ATCC),
Manassas, Virginia, USA) (3  106 cells/well in 24-well plate) in
RPMI 1640 containing 10% FBS, glutamine (25 mM) and gentamicin
(50 lg/ml) (complete medium) were incubated with either dexa-
methasone (1 nM) or dexamethasone plus various concentrations
of rOos-MIF-1.1 (0, 1 ng, 10 ng or 100 ng/ml) for 1 h. Phorbol myr-
istate acetate (PMA, 1 ng/ml; Sigma) or PMA plus lipopolysaccha-
ride (LPS, 100 ng/ml; Sigma) was then added and incubated for
an additional 4 h. Total RNA was extracted using the Trizol reagent
(Invitrogen) and subsequently treated with RNase-free DNase I
(Invitrogen) to remove contaminating genomic DNA prior to real-
time quantitative PCR (qPCR).
The inhibitory effect of rOo-MIF-1.1 on aPBMC migration was
determined using the polycarbonate membrane-based trans-well
chemotaxis inserts with 5 lm pore size and 6.5 mm in diameter
(Corning, Lowell, MA, USA), as previously reported (Nisbet et al.,
2010). In brief, 700 ll of the complete medium was added to wells
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placing inserts in the wells. aPMBCs (106 cells per well) in 100 ll
containing medium alone, 0.1 lg/ml of rOo-MIF-1.1, or 1.0 lg/ml
of rOo-MIF-1.1 were then added to the inserts (which served as
the upper chamber). Following incubation at 37 C in the presence
of 5% CO2 for 4 h, the inserts were rinsed gently three times with
PBS (kept at RT), fixed in methanol at 20 C for 1 h and air-dried
overnight. The membrane was then removed, stained with
Differential Quik Stain Kit (Modified Giemsa, Electron Microscopy
Sciences (EMS), Hatfield, PA, USA) and mounted onto a glass slide.
Migrated cells in each membrane were counted under a
microscope at 100 magnification.
2.10. q-PCR analysis of cytokine gene expression
Total RNA (1 lg) was used to synthesise cDNA with an oligo
d(T)18 primer using a M-MuLV Reverse Transcriptase Kit (Prome-
ga). qPCR was performed using SsoAdvanced SYBR Green Supermix
(Bio-Rad, Hercules, California, USA) and the Bio-Rad CFX96 Real-
time system (Bio-Rad). cDNA (100 ng total RNA equivalent) was
added to a 20 ll reaction with bovine or human cytokine primers
reported previously (Leutenegger et al., 2000; Roger et al., 2005;
Thacker et al., 2007). The actin gene was used to normalise loading.
The bovine cytokine and actin q-PCR was performed using these
conditions: 95 C for 3 min followed by 40 cycles of 15 s denatur-
ation at 95 C and 1 min annealing at 60 C. The human cytokine
q-PCR was conducted using the following conditions: 95 C for
3 min followed by 45 cycles of 15 s at 95 C, 30 s at 62 C, and
15 s at 74 C. Data were analysed with the 2DDCt method as
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Fig. 2. Characterization of recombinant Ostertagia ostertagi macrophage migration
inhibitory factor -1.1 (rOos-MIF-1.1) and its mutants by (A) SDS–PAGE and size
exclusion chromatography (SEC)–HPLC, and (B) chemical cross-linking. (A) SEC–
HPLC purification (chromatograph) and SDS–PAGE analysis (insert) of rOos-MIF-1.1
(solid line) and rOos-MIF-1.1P1G (dotted line). The peak retention times in min are
indicated for both rOos-MIF-1.1 and rOos-MIF-1.1P1G. SDS–PAGE insert: M,
molecular weight markers; Lane 1, rOos-MIF-1.1; Lane 2, rOos-MIF-1.1P1G. (B)
Silver staining analysis of cross-linked rOos-MIF-1.1 and its mutants separated on
4–12% NuPAGE gels. (a) rOos-MIF-1.1; (b) rOos-MIF-1.1P1G; (c) rOos-MIF-1.1P1+P.
A total of 2 lg/ml of rOos-MIF-1 in 1 ml total volume was used in the cross-linking
reactions. Lane 1, protein fixed by NaBH4 without 1% glutaraldehyde; Lane 2,
protein treated with 1% glutaraldehyde without NaBH4 fixation; Lane 3, protein
treated with 1% glutaraldehyde followed by NaBH4 fixation; Lane 4, untreated
protein. The arrows indicate positions of monomers (M), dimers (D) and trimers (T).
(C) Densitometric analysis of monomers, dimers and trimers of rOos-MIF-1.1 (I),
rOos-MIF-1.1P1G (II) and rOos-MIF-1.1P1+P (III) determined by cross-linking assay
from two independent experiments. % total represents the percentage of mono-
mers, dimers or trimers in the total of monomers, dimers and trimers detected.
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Fig. 3. Western blot analysis of (A) recombinant Ostertagia ostertagi macrophage
migration inhibitory factor-1.1 (rOos-MIF-1.1) and its mutants, (B) cross-reactivity
of anti-rOos-MIF-1.1 to recombinant Neospora caninum MIF (rNcMIF) and mouse
macrophage migration inhibitory factor, and (C, D) native Oos-MIF-1 in O. ostertagi
at various stages of the life cycle. (A) Western blot analysis of rOos-MIF-1.1 and its
mutants (0.1 lg/lane) using the sheep anti-rOos-MIF-1.1 antibody. Lane 1, rOos-
MIF-1.1; Lane 2, rOos-MIF-1.1P1G; Lane 3, Oos-MIF-1.1P1+P. (B) Cross-reactivity of
anti-rOos-MIF-1.1 to macrophage migration inhibitory factors (0.1 lg/lane) from
other species. Lane 1, rOos-MIF-1.1; Lane 2, rNcMIF; Lane 3, mouse macrophage
migration inhibitory factor. (C) Western blot analysis of native Oos-MIF-1. Egg, O.
ostertagi embryonated egg homogenate; L3, homogenate of infective O. ostertagi
L3s; Adult, lysate of O. ostertagi adult worms; ES, excretory/secretory (ES) product of
O. ostertagi adult worms, which was concentrated from the culture medium using
the trichloroacetic acid precipitation method. An equal amount of total protein
(7.8 lg) was loaded in each lane except for ES. The amount of Oos-MIF-1 in Egg, L3
and Adult is expressed as mean integrated O.D. ± S.E.M. Data represent four
independent experiments. ⁄P < 0.01.
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2.11. Statistical analysis
Data were analysed by GraphPad InStat software (La Jolla, CA,
USA) using one-way ANOVA with Student–Newman–Keuls
Multiple Comparisons Test. Unless otherwise indicated, all data
are presented as mean ± S.E.M. A probability of less than 0.05
was considered statistically significant.
3. Results
3.1. Oos-MIF genes and proteins
There are two cDNA sequences (BQ457770, BQ457911), one EST
sequence (OS00782) and two mRNA transcripts (Oost_isotig14764,
Oost_isotig14765), coding for an Oos-MIF, all of which are partial
sequences, lacking the 50 terminus. The cDNA OS00782 is the lon-
gest sequence, missing only five nucleotides at the 50 terminus
compared with Tci-mif-1 cDNA (CBI68362A) of the sister parasite
T. circumcincta, whose nucleotide sequence is over 90% similar to
that of this Oos-mif (Nisbet et al., 2010). Inasmuch as all MIFs iden-
tified thus far have a conserved Pro at the second predicted amino
acid (aa) position, it was reasoned that the first two aas for Oos-
MIF are Met and Pro. Methionine is encoded by the unique codon
of ATG. We chose CCG as the Pro codon because the first base of
cDNA OS00782 is a G. Thus, the 50 sequence of ATGCCGGTTTTCTC
of Oos-mif was used to synthesise the 50 primer. A full length
Oos-mif cDNA (348 bp) was amplified from O. ostertagi adult worm





















Fig. 4. Immunohistochemical localisation of Ostertagia ostertagimacrophage migration inhibitory factor-1 (Oos-MIF-1) in 10% neutral formalin-fixed O. ostertagi adult worms.
Deparaffinised tissue sections were incubated with sheep anti-rOos-MIF-1.1 antibody (1:1,000; A–C, magnification, 100; D–F, magnification, 400) or pre-bleed sheep
serum (1:1,000) (G, H, 400; I, 100). Oos-MIF-1-specific staining was visualised using a rabbit anti-sheep IgG-horseradish peroxidase and the Dako AEC substrate
chromagen. The dark-brown color represents the presence of Oos-MIF-1 and the blue color represents counter staining by hematoxylin. cut., cuticle; pha., pharynx; hyp.,
hypodermis; mus., muscle; rep., reproductive tract; int., intestine; pse., pseudocelom; ova., ovary; ute., uterus; tes., testis.
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sequence was identical to that of Tci-MIF-1, although this Oos-mif
gene differs from that of Tci-mif-1 by 14 nucleotides, all of which
are synonymous (Fig. 1B). Alignment of aa sequences from selected
mammals, parasitic nematodes and a free-living nematode indi-
cates that the Oos-MIF characterised in this study shares 40–42%
identity with mammalian MIFs and 44–55% with the nematode
MIFs (Fig. 1A). Phylogenetic analysis revealed that this Oos-MIF
should belong to the MIF1 family, based on its similarity to B.
malayi (Bma)-MIF-1 (AAB60943) and C. elegans (Cel)-MIF-1
(NP_499536) (Figs. 1A, D). Furthermore, an Oos-MIF-1 isoform (en-
coded by OS04085 and BQ457552) is also present, which shares an
overall sequence identity of 93% with the Oos-MIF-1 studied herein
(Fig. 1C, Db). Therefore, we designated the Oos-MIF-1 cloned and
characterised in the present study as Oos-MIF-1.1 (Fig. 1Da), and
the Oos-MIF-1 encoded by OS04085 and BQ457552 as Oos-MIF-
1.2 (Fig. 1Db). Oos-MIF-1.2 is identical to Oos-MIF-1.1 from aa 23
to 115 except for aa residues 108 and 110, and has a deletion
between aa 11 and 19 (Fig. 1C). Importantly, Oos-MIF-1.2 appears
to lack a Pro at position 1; however, this feature needs to be further
confirmed when the full coding sequence for Oos-MIF-1.2 becomes
available (Fig. 1C). Additional analysis demonstrated that
there is an Oos-MIF-2 (Oost_isotig21269), closely related to
Cel-MIF-2, Bma-MIF-2, and Asu-MIF-2 (Figs. 1C, Db). Oos-MIF-2
is only 95 aa in length with deletions at aa 86–94 and aa
105–115 relative to that of Oos-MIF-1.1, and shares a limited aa
sequence identity of 20% and 15.8% with Oos-MIF-1.1 and
Oos-MIF-1.2, respectively. However, Oos-MIF-2 is 45.3% identical
to Cel-MIF-2a (Fig. 1C, Db).
The translation initiating Met1 is removed from native MIF by
proteolytic processing, exposing Pro as the first aa residue. Cleavage
of Met1 also occurs in recombinant MIF expressed in E. coli
(Bernhagen et al., 1994; Sun et al., 1996b). Thus, the first aa of
Oos-MIF-1.1 is Pro1 (Fig. 1A). The calculated Oos-MIF-1.1molecular
mass is 12.2 kDa with a predicted pI of 6.59. Oos-MIF-1.1 does not
appear to contain a conventional signal peptide (SignalP 4.0,
http://www.cbs.dtu.dk/services/SignalP-4.1/). Similar to most
nematode MIFs, Oos-MIF-1.1 and Oos-MIF-1.2 possess four (Pro1,
Lys32, Ile64 and Tyr95) out of six of the critical aas for tautomerase
activity in mammalian MIF (Fig. 1A). Oos-MIF-2 only retains Lys32
and Ile64 (Fig. 1B). The Cys57XXCys60 motif which is responsible
for mediating the catalytic oxidoreductase activity in mammalian
MIFs is absent from all Oos-MIFs, only retaining Cys57 in
Oos-MIF-1s (Fig. 1A).
3.2. Expression, purification and chemical cross-linking of rOos-MIF-
1.1 and its mutants
Soluble rOos-MIF-1s were expressed in E. coli BL21 (DE3) at
30 C in the presence of 1 mM IPTG and purified to 95–99% homo-
geneity by size exclusion chromatography (SEC)-HPLC. rOos-MIF-
1.1, rOos-MIF-1.1P1G and rOos-MIF-1.1P1+P exhibited a similar
molecular mass of approximately 12 kDa (Fig. 2A, B); however,
rOos-MIF-1.1P1G had an average chromatographic retention time
of 41.5 min which is 13 min longer than that for rOos-MIF-1.1
(28 min) (Fig. 2A). rOos-MIF-1.1P1+P had a retention time similar
to that of rOos-MIF-1.1 (data not shown). Mammalian MIFs likely
exist as a mixture of monomers, dimers and trimers, although
equilibrium density sedimentation studies are consistent with a
predominant trimer form (Mischke et al., 1998; Philo et al.,
2004). To characterise the oligomerisation state of rOos-MIF-1.1,
purified proteins were cross-linked and analysed under reducing
conditions (Fig. 2B). The results showed that in the absence of
cross-linking, rOos-MIF-1.1 exists predominantly as a monomer.
Following cross-linking, rOos-MIF-1.1 and its mutants exhibited
three main forms: monomers, dimers and trimers, with the
monomer being the predominant form (Fig. 2B, C). Some minor
products of higher oligomerisation also were detected by this
method (Fig. 2B). Glutaraldehyde slightly increased the amount
of dimers and trimers in rOos-MIF-1.1 and rOos-MIF-1.1P1G, but
appeared to decrease oligomerisation in rOos-MIF-1.1P1+P
(Fig. 2B). Overall, rOos-MIF-1.1 had the highest level of trimers,
whereas rOos-MIF-1.1P1G and rOos-MIF-1.1P1+P had slightly
Fig. 5. Internalisation of recombinant Ostertagia ostertagi macrophage migration
inhibitory factor -1.1 (rOos-MIF-1.1) by macrophages. Bovine (BoMac, A–D) and
murine (RAW264.7, E–H) macrophage cell lines were pre-incubated with 10 lg/ml
of rOos-MIF-1.1 overnight and fixed with methanol/acetone at 20 C for 20 min
followed by immunostaining with sheep anti-rOos-MIF-1.1 antibodies. (A, C, E and
G) Bright field/phase images. (B, D, F and H) Overlay of the matching bright field/
phase and fluorescence staining images. (A, B) BoMac and (E, F) RAW247.6 cells
were incubated with rOos-MIF-1.1 followed by staining with pre-immune sera
(1:800), rabbit anti-sheep IgG-DyLight 488 and DAPI. (C, D) BoMac and (G, H)
RAW247.6, cells were incubated with rOos-MIF-1.1 followed by staining with sheep
anti-rOos-MIF-1.1 antibody (1:800) and by detection with rabbit anti-sheep IgG-
DyLight 488 and DAPI. nuc., nucleus; cyt., cytoplasm. Controls also included cells
incubated without rOoMIF1 and stained with rabbit anti-sheep IgG-DyLight 488
alone or sheep anti-OoMIF antibody (1:800) followed by detection by rabbit anti-
sheep IgG-DyLight 488 and DAPI. No specific staining was seen in controls.
Magnification, 400.
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lower levels of trimers and concomitantly higher levels of
monomers (Fig. 2C).
3.3. Stage-specific expression of Oos-MIF-1
A sheep-anti-rOos-MIF-1.1 antibody recognised SEC-HPLC-
purified rOos-MIF-1.1 (Fig. 3A, B, Lane 1), rOos-MIF-1.1P1G
(Fig. 3A, Lane 2) and rOos-MIF-1.1P1+P (Fig. 3A, Lane 3) as single
bands of 12 kDa. This antibody is specific for Oos-MIF-1 and
corresponding mutants because it lacked cross-reactivity with a
protozoan MIF (recombinant N. caninum MIF) (Qu et al., 2013) or
a mammalian MIF (recombinant mouse MIF; R&D Inc.) (Fig. 3B,
Lanes 2, 3). Oos-MIF-1 was detectable in lysates of O. ostertagi
embryonated eggs, infective L3s, and adult worms (Fig. 3C).
Oos-MIF-1 was clearly detectable in O. ostertagi adult worm
secretory/excretory (ES) product prepared at 37 C (Fig. 3C), but
not in that prepared at 4 C (data not shown). Oos-MIF-1 level
was higher (P < 0.01) in adult worms than in embryonated eggs
and L3s (Fig. 3D), when compared using equal quantities of crude
proteins prepared from each stage of the parasite. It was difficult
to estimate the concentration of total ES proteins used due to the
limited quantity available; consequently, Oos-MIF-1 in adult ES
protein was not compared. The pre-bleed sera were used as
negative controls and no proteins were detected by these sera
under similar dilutions (data not shown).
3.4. Immunolocalisation of Oos-MIF-1
Oos-MIF-1 was primarily localised to the hypodermis/muscle
layer (Fig. 4A, B), intestine (Fig. 4C, F) and reproductive tract
(Fig. 4C–F) of adult worms. Within the reproductive tract, Oos-
MIF-1 appeared to be associated with eggs/embryonated eggs in
the ovary/uterus and unidentified cells/tissues in the uterus and
testes (Fig. 4D–F). Oos-MIF-1 was not detected in cuticles and
pharynx (Fig. 4A, B, F). To determine whether rOos-MIF-1.1 was ta-
ken up and internalised by macrophages, bovine (Fig. 5A–D) and
mouse (Fig. 5E–H) macrophage cell lines were pre-incubated over-
night with or without 10 lg/ml of rOos-MIF-1.1. Staining was not
detected in cells incubated with rOos-MIF-1.1 and stained by
secondary antibody alone (data not shown) or pre-immune sera
(Fig. 5B, F), or in cells incubated with medium alone and stained
with immune or pre-immune sera (data not shown). rOos-MIF-
1.1 was detected specifically in the cytoplasm of permeabilised,
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Fig. 6. Tautomerase activity of recombinant Ostertagia ostertagimacrophage migration inhibitory factor-1.1 (rOos-MIF-1.1) and its mutants using L-dopachrome methyl ester
as a substrate. (A) Tautomerase activity of mouse macrophage migration inhibitory factor as a positive control at a final concentration of 0.5 lg/ml. (B) Tautomerase activity
of rOos-MIF-1.1 (0.5 or 2 lg/ml), rOos-MIF-1.1P1G (2 lg/ml), or rOos-MIF-1.1P1+P (2 lg/ml). (C) Tautomerase activity of rOos-MIF-1.1 subjected to Triton X-114 extraction
for lipopolysaccharide removal (rOos-MIF TX) was compared with rOos-MIF-1.1 without Triton X-114 treatment. Time- (D) and dose-dependent (E) inhibition of rOos-MIF-
1.1 tautomerase activity by sheep anti-rOos-MIF-1.1 antibody. rOos-MIF-1.1 (2 lg/ml) pre-incubated with or without different dilutions (1:2, 1:4 and 1:8) of sheep anti-rOos-
MIF-1.1 antibody (Ab) or with pre-bleed (PB) sheep sera (pre-immune) (1:2) at room temperature for 1 h followed by tautomerase assay. PBS alone or pre-bleed sera diluted
in PBS (1:2) was used as the negative control throughout the experiments. The data represent three independent experiments.
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3.5. rOos-MIF-1.1 exhibits tautomerase activity
Recombinant mouse MIF used as a positive control in the tau-
tomerase assay demonstrated tautomerase activity of 250 lmol/
min/mg (Fig. 6A). The tautomerase activity of rOos-MIF-1.1 was
84.3 lmol/min/mg at 0.5 lg/ml and 90.5 lmol/min/mg at 2 lg/
ml (Fig. 6B). rOos-MIF-1.1 tautomerase activity appeared to be
nearly three-fold lower than that of mouse MIF, when compared
at the 0.5 lg/ml of protein level (Fig. 6A, B). Both rOos-MIF-
1.1P1G and rOos-MIF-1.1P1+P mutants showed no detectable tau-
tomerase activities (Fig. 6B). Since rOos-MIF-1.1 was treated with
Triton X-114 to remove endotoxin, experiments were performed
to determine whether this treatment affected the tautomerase
activity. As shown in Fig. 6C, Triton X-114-treated rOos-MIF-1.1
at 0.5 lg/ml and 2 lg/ml concentrations had tautomerase activi-
ties of 92.8 lmol/min/mg and 98.5 lmol/min/mg, respectively,
which were comparable with those of Triton X-114 non-treated
rOos-MIF-1.1 (Fig. 6B). The mouse MIF tautomerase activity de-
creased from 315 to 109 lmol/min/mg, a reduction of 65%, in the
presence of 400 lM ISO-1 which is a specific inhibitor of the mam-
malian MIFs (Al-Abed et al., 2005). The inhibitory effect of ISO-1 on
rOos-MIF-1.1 tautomerase activity was only 32.4 ± 7.7% (four rep-
licates), a decrease from 100.8 ± 10.3 to 66.5 ± 5.8 lmol/min/mg.
The sheep anti-rOos-MIF-1.1 antibody was also tested for the inhi-
bition of tautomerase activity of rOos-MIF-1.1. This antibody inhib-
ited rOos-MIF-1.1 tautomerase activity in a dose-dependent
manner (Fig. 5D, E). PBS or pre-immune sera had no effect on
rOos-MIF-1.1 activity (Fig. 6E).
3.6. rOos-MIF-1.1 competes with rhMIF for binding to human CD74
Similar to rhMIF, rOos-MIF-1.1 competed with biotinylated
rhMIF for binding to the human MIF receptor ectodomain (soluble
CD7473–232) in a dose-dependent manner (Fig. 7). rOos-MIF-
1.1P1G, which had Pro at position 2 mutated to Gly, had very
low binding to the human MIF receptor (Fig. 7).
3.7. Regulation of glucocorticoid effect and inhibition of aPBMC
migration by rOos-MIF-1.1
rOos-MIF-1.1, at all concentrations tested, restored dexametha-
sone-suppressed TNFa and IL-8 induction by LPS in U937 cells
(Fig. 8Aa, b). Similarly, rOos-MIF-1.1 reversed the dexametha-
sone-suppressed TNFa induction by LPS in bovine aPBMC at the
dose of 10 ng/ml (Fig. 8Ac), but had no apparent effect on the IL-
8 response (Fig. 8Ad). rOos-MIF-1.1 at 1 lg/ml, but not 0.1 lg/ml,
inhibited random migration of bovine aPBMCs compared with
medium alone (Fig. 8B).
4. Discussion
MIF is a conserved protein throughout the plant and animal
kingdoms as shown by much research in the past decades (Lolis
and Bucala, 2003) and recent genome sequencing (Tabata et al.,
2000; Schnable et al., 2009). MIF also has been described in nema-
todes and protozoa, some of which are animal and/or human par-
asites (Vermeire et al., 2008). While information for the definitive
functions of mammalian MIFs is progressively accumulating, the
functions of MIFs from the free-living and parasitic nematodes
are largely unknown. The present study characterised a MIF ortho-
log, Oos-MIF-1.1, from the cattle abomasal parasite, O. ostertagi.
From analysis of all available Oos-MIF transcript sequences, we
found that there are at least three distinct Oos-MIF transcripts,
with two (Oos-MIF-1.1 and Oos-MIF-1.2) belonging to the MIF-1
family and one (Oos-MIF-2) to the MIF-2 family based on sequence
similarities with the Cel-MIFs. Since Oos-MIF-1.1 and Oos-MIF-1.2
are highly conserved, we speculate they share similar immunologic
epitopes, as well as similar bio-activities given the similarities in
their primary aa sequences. The biological activities of the Oos-
MIF-2 are currently unknown and await further investigation. It
is worth noting that since the C-terminus (residues 105-114) is
crucial to the catalytic activity and stability of human MIF (El-Turk
et al., 2008), the biological properties of Oos-MIF-2 with an absent
C-terminus are difficult to predict. In addition, Oos-MIF-1.1 was se-
lected for characterisation in the present study because Oos-MIF-
1.2 may be missing the catalytic Pro1 residue and Oos-MIF-2 lacks
the C-terminus considered essential for stable oligomerisation. We
believe the present study is the first to characterise the Oos-MIF
isoforms based on cDNA and mRNA sequences available.
Oos-MIF-1.1 possesses four of six aa residues critical for the
tautomerase catalytic activity, including Pro1, Lys32, Ile64 and
Tyr95 (Bendrat et al., 1997). Similar to the findings in N. caninum
MIF reported previously (Qu et al., 2013), a point mutation at
Pro1 led to prolonged retention time for rOos-MIF-1.1P1G on
SEC–HPLC and reduced oligomerisation. Intrigued by this observa-
tion, we further determined whether addition of a Pro2 between
Pro1 and Val3 would change the chromatographic profile. The re-
sults indicate that addition of Pro2 did not alter its retention time
on SEC-HPLC nor its mobility on SDS-PAGE. However, oligomeri-
sation as shown by the cross-linking experiments was reduced in
the absence of Pro1 or in the presence of Pro2. This is consistent
with recent reports that Pro is essential for protein configuration
and oligomerisation (Bernacchi et al., 2011; Shukla et al., 2012).
The Cys57XXCys60 motif is absent from all Oos-MIFs, thus the
lack of oxidoreductase activity by rOos-MIF-1.1 was not confirmed
in the present study and remains to be empirically elucidated.
rOos-MIF-1.1 was fully functional as a tautomerase, although it



















Fig. 7. Competitive binding of recombinant Ostertagia ostertagi macrophage
migration inhibitory factor -1.1 (rOos-MIF-1.1) and mutant rOos-MIF-1.1P1G to
the human MIF receptor ectodomain (soluble CD74) using an in vitro capture assay.
Purified recombinant human macrophage migration inhibitory factor (rhMIF, filled
triangle), rOos-MIF-1.1 (open triangle) or rOos-MIF-1.1P1G (filled square) ranging
from 0.5 to 70 lg/ml were used to compete with biotinylated rhMIF (2.3 lg/ml) for
the human macrophage migration inhibitory factor receptor ectodomain which was
coated on the plate. Percentage binding is expressed as (test macrophage migration
inhibitory factor binding O.D.  background O.D.)/(total binding O.D.  background
O.D.)  100, where the wells for test macrophage migration inhibitory factor
binding contained a fixed concentration of biotinylated rhMIF and different
concentrations of test macrophage migration inhibitory factor, wells for total
binding contained biotinylated rhMIF alone, and the wells for background reading
contained medium or unlabeled test macrophage migration inhibitory factor only.
Each data point represents the mean percentage of binding with a pooled S.E.M. of
4.8% from two independent experiments.
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much less active than other nematode MIFs catalysing the same
tautomerase substrate (Tan et al., 2001; Cho et al., 2007); however,
it is more active than almost all of the protozoan MIFs with respect
to tautomerase activity (Augustijn et al., 2007; Richardson et al.,
2009; Qu et al., 2013; Sommerville et al., 2013). Both the absence
of Pro1 and presence of Pro2 rendered Oos-MIF-1.1 non-functional,
suggesting that Pro1 is critical in its structure and tautomerase
activities, but not the two aas (Asn97 and Val106 that are absent
from Oos-MIF-1.1) that are critical to that of the mammalian MIFs.
Intriguingly, Pro1, Lys32, Ile64 and Tyr95 are also conserved
between mammalian MIFs and Neospora MIF, but it is apparent
that this conservation is not sufficient for NeosporaMIF to be active
as a tautomerase (Qu et al., 2013). The results suggest that enzy-
matic centers of the mammalian MIFs and those of the nematodes
are structurally different. Crystal structures of MIFs indicate that
the trimer is the functional form of MIF (Sun et al., 1996b). The
reduction in tautomerase activity in rOos-MIF-1.1 mutants may
also be related to reduced trimer formation as shown in the
present study or the lack of an appropriate catalytic pocket
(Lubetsky et al., 1999). Interestingly, the mammalian MIF-specific
inhibitor, ISO-1(Lubetsky et al., 2002), was only partially effective


















































































































































Fig. 8. Counter-glucocorticoid effect of, and cell migration inhibition by, recombinant Ostertagia ostertagi macrophage migration inhibitory factor-1.1 (rOos-MIF-1.1). (A)
Counter-glucocorticoid effect. Human monocyte cell line U937 (a, b) and fresh bovine adherent peripheral blood mononuclear cells (c, d) were treated with dexamethasone
(DEX, 1 nM) alone, phorbol myristate acetate (PMA; 1 ng/ml) + lipopolysaccharide (LPS; 100 ng/ml), DEX + PMA + LPS, or DEX + PMA + LPS in combination with increasing
concentrations of rOos-MIF-1.1 (1 ng/ml; 10 ng/ml; 100 ng/ml), levels of TNFa (a, c) and IL-8 (b, d) transcripts were analysed by real-time quantitative PCR. Data represent
mean expression levels (2DDCt) ± S.E.M. from three independent experiments. ND, not determined; ⁄P < 0.05; ⁄⁄P < 0.001. (B) Inhibition of adherent peripheral blood
mononuclear cells migration. Fresh adherent peripheral blood mononuclear cells in quadruplicates were pre-mixed with 1 lg or 0.1 lg/ml rOos-MIF-1.1 prior to addition to
polycarbonate membrane-based trans-well chemotaxis inserts (see Section 2.9) and cultured for 4 h. Cells in each fixed and stained insert membrane were counted in four
viewing fields. Results represent mean ± S.D. of three independent experiments. ⁄P < 0.05.
G. Qu et al. / International Journal for Parasitology 44 (2014) 355–367 365
anti-rOos-MIF-1.1 antibody was able to completely abrogate the
rOos-MIF-1.1 tautomerase activity. These results indicate again
that the catalytic centers of the mammalian MIFs and that of
Oos-MIF-1 may be structurally different, and antibody binding is
a powerful tool to study the tautomerase-related activities.
As shown, Oos-MIF-1.1 and Oos-MIF-1.2 are highly similar but
different from the Oos-MIF-2; therefore, the anti-rOos-MIF-1.1
antibody produced in this research likely recognises both Oos-
MIF-1.1 and 1.2 in Western blotting and immunohistochemistry
but not Oos-MIF-2. For this reason, Oos-MIF detected in the para-
site by this antibody is referred to as Oos-MIF-1 collectively. Oos-
MIF-1 is present at all stages of development examined, with the
highest levels expressed at the adult stage. These results are differ-
ent from those of Tci-MIF-1, where Tci-mif-1 transcript and Tci-
MIF-1 appear to be higher in the egg and/or L3 than in the adult
worm (Nisbet et al., 2010). In addition, this pattern of expression
of Oos-MIF-1 also seems to differ from those of the Cel-mif-2 and
Cel-mif-3 genes, in which these genes are highly expressed in the
dauer larvae stage (Marson et al., 2001). This study clearly showed
that Oos-MIF-1 is also present at low levels in adult ES product and
that it is only secreted at physiological temperatures relative to ES
protein prepared at 4 C, suggesting that ES Oos-MIF-1 is actively
released and not the result of leakage from live and/or dead worms.
However, Tci-MIF-1 protein was not detected in the ES products of
T. circumcincta larvae or adult worms (Smith et al., 2009; Nisbet
et al., 2010). Due to the lack of a signal peptide, Oos-MIF-1 detected
in the ES preparation may be secreted using non-classical
pathways.
A recent report on O. ostertagi transcriptomes indicates that
Ostertagia MIF-like transcripts (as clustered under OS00282.cl)
are more abundant in L4s (10 transcripts) than in L3s (one tran-
script) (Abubucker et al., 2009). However, the OS00282.cl cluster
contains seven distinct sequences (http://www.nematode.net),
four of which belong to the 40S ribosomal protein S17 family,
one that is not translatable, and two (OS0782 and OS04085) that
coincide with the Oos-MIF-1.1 and Oos-MIF-1.2 identified here,
respectively. Oos-MIF-1 was not determined in L4s in the present
study, and additional research is needed to show the differential
expression of this molecule in L4s in comparison to other stages.
Oos-MIF-1 was localised to the hypodermis/muscle layer,
reproductive tract and intestine of the adult worm, which is consis-
tent with the presence of Oos-MIF-1 in ES products and worm
lysate. This pattern of distribution in the adult worm is consistent
with that in T. circumcincta (Nisbet et al., 2010), B. malayi and
C. elegans (Pastrana et al., 1998; Marson et al., 2001), which sug-
gests a common role for this molecule in worm development. Fur-
thermore, following incubation of the rOos-MIF-1.1 with
macrophages, this recombinant protein was specifically localised
to the cytoplasm of the permeabilised macrophages, suggesting
that rOos-MIF-1.1 was internalised by those cells. This interaction
of Oos-MIF-1.1 with host immune cells was further verified by its
specific binding to human CD74, a MIF receptor (Leng et al., 2003).
This result demonstrates that the Oos-MIF-1.1 secreted by
O. ostertagi in the abomasal tissue can interact with host immune
cells and in so doing regulate local immunity. Indeed, the present
study on Oos-MIF-1 and the previous report on Tci-MIF-1 (Nisbet
et al., 2010) demonstrated the immunoregulatory functions of
nematode-derived MIF in cytokine production and monocyte
migration, respectively. Recently, this same group has demon-
strated an efficacious cocktail vaccine against T. circumcincta,
which contained recombinant Tci-MIF-1 as one of the multiple
recombinant proteins in the vaccine (Nisbet et al., 2013). Although
the efficacy of Tci-MIF-1 alone was not shown, this research pre-
sented optimism to continued investigation in vaccine-based
control of nematode parasite infection in ruminants. Taken
together, further research investigating the role of Oos-MIFs during
development and infection, and their potential as vaccine candi-
dates is warranted given that antibodies to Oos-MIF-1 do not
cross-react with host MIF, but are capable of interfering with
Oos-MIF function.
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